MiMedx

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

Retrieved on: 
Thursday, March 21, 2024
Growth, Partnership, Anatomy, Webcast, Travel, PRS, Matrix, Sale, Hernia, MiMedx, Event, FDA, Video game

“The recalibration of our sales force over 2023 has led to increased productivity and an improved mix of sales across our product portfolio.

Key Points: 
  • “The recalibration of our sales force over 2023 has led to increased productivity and an improved mix of sales across our product portfolio.
  • 2023 was a great year that sets TELA Bio up for even more achievement in 2024!”
    Revenue was $17.0 million in the fourth quarter of 2023, an increase of 46% compared to the same period in 2022.
  • Operating expenses were $23.9 million in the fourth quarter of 2023, compared to $17.6 million in the same period in 2022.
  • TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, March 21, 2024 to discuss its fourth quarter and full year 2023 financial results.

Spectral AI Appoints Peter M. Carlson as CEO

Retrieved on: 
Thursday, February 29, 2024
Momentum, CFO, UKCA, Burn, Artificial intelligence, MiMedx, Spectral, FDA, Growth, MDAI, Brings, Highlight, Senior advisor, Classification, Burns, DFU, Corporation

DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its Board of Directors (the “Board”) has appointed Peter M. Carlson, Spectral AI’s current Chief Financial Officer, as Chief Executive Officer and a member of the Board. He succeeds Wensheng Fan, who, after 14 years with Spectral AI, including nearly four as CEO, is transitioning to Chief Innovation Strategist and Senior Advisor to the CEO. Vincent S. Capone, Spectral AI’s General Counsel and Corporate Secretary, will assume the additional role of Chief Financial Officer.

Key Points: 
  • He succeeds Wensheng Fan, who, after 14 years with Spectral AI, including nearly four as CEO, is transitioning to Chief Innovation Strategist and Senior Advisor to the CEO.
  • Vincent S. Capone, Spectral AI’s General Counsel and Corporate Secretary, will assume the additional role of Chief Financial Officer.
  • He joined Spectral AI as CFO in January 2024 following the Company’s debut on the NASDAQ Global Market.
  • “In his short time here, Pete has already distinguished himself as a skilled and experienced leader and a tremendous asset to Spectral AI.

MDXG INVESTOR NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG

Retrieved on: 
Tuesday, January 23, 2024
Titan, Letter, Advertising, MiMedx, Plaintiff, FDA, News

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21901 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

Retrieved on: 
Friday, January 26, 2024
Pomerantz, LLP, Prior, Letter, MiMedx, FDA, News

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG).

Key Points: 
  • NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG).
  • The investigation concerns whether MiMedx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation – MDXG

Retrieved on: 
Friday, January 26, 2024
Titan, Letter, Advertising, MiMedx, FDA, News

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21901 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21901 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

MDXG LOSS ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation – MDXG

Retrieved on: 
Saturday, January 20, 2024
Titan, Letter, Advertising, MiMedx, FDA, News

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21901 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21901 or call Phillip Kim, Esq.
  • toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

Retrieved on: 
Thursday, January 18, 2024
Pomerantz, LLP, Letter, MiMedx, FDA, News

NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG).

Key Points: 
  • NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG).
  • The investigation concerns whether MiMedx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

MiMedx Group Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Retrieved on: 
Wednesday, January 17, 2024
Block & Leviton, Food, MiMedx

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MiMedx Group, Inc. (NASDAQ: MDXG) for potential securities law violations.

Key Points: 
  • BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MiMedx Group, Inc. (NASDAQ: MDXG) for potential securities law violations.
  • Investors who have lost money in their MiMedx Group, Inc. investment should contact the firm to learn more about how they might recover those losses.
  • Anyone who purchased MiMedx Group, Inc. securities and has lost money may be eligible, whether or not they have sold their investment.
  • Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG

Retrieved on: 
Wednesday, January 17, 2024
Class Action Lawsuit, Professional Services, Legal, Titan, Letter, Advertising, MiMedx, FDA, News

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21901 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

MIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, January 16, 2024
Letter, P.C, MiMedx, FDA, Telephone, News

NEW YORK, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) on behalf of MiMedx stockholders.

Key Points: 
  • NEW YORK, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) on behalf of MiMedx stockholders.
  • Our investigation concerns whether MiMedx has violated the federal securities laws and/or engaged in other unlawful business practices.
  • Click here to participate in the action.
  • There is no cost or obligation to you.